Eli Lilly

Eli Lilly

Verified
Discovery, development, manufacture, and sale of products in pharmaceutical products business segment

Launch date
Employees
Market cap
$307.2b
Net debt
($10.1b)
Firm valuation
$317.4b (Public information from Oct 2022)
Indianapolis Indiana (HQ)
Corporate Venture Fund: Lilly Ventures

Financials

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022E
Revenues-22.9b24.6b22.3b24.5b28.3b28.2b
% growth--7 %(9 %)10 %15 %-
EBITDA-6.5b7.8b7.6b8.6b9.6b10.1b
% EBITDA margin-29 %32 %34 %35 %34 %36 %
Profit-(204m)3.2b8.3b6.2b5.6b7.2b
% profit margin-(1 %)13 %37 %25 %20 %26 %
EV / revenue-4.1x4.9x6.2x6.8x8.8x8.1x
EV / EBITDA-14.4x15.5x18.4x19.3x26.1x22.5x
R&D budget4.6b3.8b3.5b3.6b---
R&D % of revenue-17 %14 %16 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/AN/AIPO
*
N/AAcquisition
$375mGrant
$813mGrant
Total Funding$1.2b

Recent News about Eli Lilly

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
ARMO Bio Sciences
ACQUISITION by Eli Lilly May 2018
Alnara Pharmaceuticals
ACQUISITION by Eli Lilly Jul 2010
Zymeworks
BUYOUT by All Blue Capital May 2022
ImmunoGen
exited
Novartis Animal Health
ACQUISITION by Eli Lilly Apr 2014
BioNTech
exited
Eli Lilly
ACQUISITION by Eli Lilly Feb 2020
View 72 more